Skye Bioscience, Common Stock Probability of Future Stock Price Finishing Over 5.43
| SKYE Stock | USD 2.70 0.16 5.59% |
Skye |
Skye Bioscience, Target Price Odds to finish over 5.43
The tendency of Skye Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 5.43 or more in 90 days |
| 2.70 | 90 days | 5.43 | about 7.39 |
Based on a normal probability distribution, the odds of Skye Bioscience, to move over $ 5.43 or more in 90 days from now is about 7.39 (This Skye Bioscience, Common probability density function shows the probability of Skye Stock to fall within a particular range of prices over 90 days) . Probability of Skye Bioscience, Common price to stay between its current price of $ 2.70 and $ 5.43 at the end of the 90-day period is about 91.01 .
Given the investment horizon of 90 days Skye Bioscience, has a beta of 0.89. This usually implies Skye Bioscience, Common market returns are highly-sensitive to returns on the market. As the market goes up or down, Skye Bioscience, is expected to follow. Additionally Skye Bioscience, Common has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Skye Bioscience, Price Density |
| Price |
Predictive Modules for Skye Bioscience,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Skye Bioscience, Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Skye Bioscience,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Skye Bioscience, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Skye Bioscience, is not an exception. The market had few large corrections towards the Skye Bioscience,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Skye Bioscience, Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Skye Bioscience, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.61 | |
β | Beta against Dow Jones | 0.89 | |
σ | Overall volatility | 0.76 | |
Ir | Information ratio | -0.08 |
Skye Bioscience, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Skye Bioscience, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Skye Bioscience, Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Skye Bioscience, generated a negative expected return over the last 90 days | |
| Skye Bioscience, has high historical volatility and very poor performance | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Skye Bioscience to Present at J.P. Morgan Healthcare Conference |
Skye Bioscience, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Skye Stock often depends not only on the future outlook of the current and potential Skye Bioscience,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Skye Bioscience,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7 M | |
| Cash And Short Term Investments | 1.3 M |
Skye Bioscience, Technical Analysis
Skye Bioscience,'s future price can be derived by breaking down and analyzing its technical indicators over time. Skye Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Skye Bioscience, Common. In general, you should focus on analyzing Skye Stock price patterns and their correlations with different microeconomic environments and drivers.
Skye Bioscience, Predictive Forecast Models
Skye Bioscience,'s time-series forecasting models is one of many Skye Bioscience,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Skye Bioscience,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Skye Bioscience, Common
Checking the ongoing alerts about Skye Bioscience, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Skye Bioscience, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Skye Bioscience, generated a negative expected return over the last 90 days | |
| Skye Bioscience, has high historical volatility and very poor performance | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Skye Bioscience to Present at J.P. Morgan Healthcare Conference |
Check out Skye Bioscience, Backtesting, Skye Bioscience, Valuation, Skye Bioscience, Correlation, Skye Bioscience, Hype Analysis, Skye Bioscience, Volatility, Skye Bioscience, History as well as Skye Bioscience, Performance. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.